Northwire Canada EditionMonday, August 24, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3%
Earnings Routine +

Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26

Stonegate updates coverage on Burcon Nutrascience Corporation (BU) 4Q26

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:21 BU · 1.95 BURCON NUTRASCIENCE CORPORATION J
Executive Summary
  • Stonegate Capital Partners updates coverage on Burcon's FY26 4Q results and early FY27 commercial traction.
  • Commercial production officially launched across core protein lines (Peazazz, Puratein C, and FavaPro) in FY26.
  • 4Q26 revenue reached $0.83M CAD, up from $0.74M in 3Q26.
  • Current-quarter sales are tracking toward approximately 50% sequential growth based on April/May activity.
  • Daily production output set a new record, running roughly 60% above January-March levels.
  • Customer traction has broadened to 30+ purchasing customers and 200+ active projects across pea, canola, and fava applications.
  • Margin expansion is expected to stem from improved facility utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure.
  • Funding status stands at $6.9M completed and $3.0M undrawn, with management targeting $10M in CY26 sales.
  • The company is moving into a utilization ramp mode to achieve better fixed-cost absorption at the Galesburg site.
Material Impact
  • The news is a routine commercial update confirming the $10M CY26 sales target and highlighting sequential sales growth and production records.
  • It does not contain genuinely new market-relevant information that would re-rate the business. The operational progress was already telegraphed in prior updates (e.g., 50% QoQ sales growth, production records).
  • The stock's -16.6% drop into the FY26 earnings print suggests the market was focused on the $14.3M net loss and negative working capital. This update does not materially alter that negative financial narrative.
BU · Price
Company Overview
  • Burcon Nutrascience is a plant protein technology company that commercialized its Galesburg, Illinois production facility in FY26.
  • Core products include Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein.
  • The company is transitioning from technology development to commercial execution, leveraging a manufacturing partnership with RE ProMan LLC.
  • Target markets include ready-to-mix beverages, nutrition bars, snacks, baked goods, and plant-based foods.
Read the original news release →

More from BURCON NUTRASCIENCE CORPORATION J

Jun 24, 2026 · 16:12

494% revenue jump overshadowed by $14.3M loss, negative equity, and costly insider debt; liquidity a red flag.

Earnings Jun 16, 2026 · 08:01

Commercial scaling accelerates, but negative equity and explicit capital calls keep the risk/reward skewed to the downside.

Production / Operations Apr 20, 2026 · 08:01

Burcon NutraScience Ramps Production Amidst Cash Burn Concerns

Production / Operations Feb 27, 2026 · 20:10

Burcon closes $2.75M second tranche of placement

Financings Feb 27, 2026 · 16:38

Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million

Financings Feb 20, 2026 · 15:34

Burcon Announces Results of Shareholder Meeting

Financings